Analyst consensus rating
iBio Analyst Rating: Strong Buy
IBIO is rated Strong Buy by 8 analysts with a $5.53 target. As of 2026-08-30.
Direct answer
iBio's consensus rating is Strong Buy.
8 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $5.53.
Forecast evidence checked August 30, 2026.
Get free iBio email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $1.36
- Average price target
- $5.53
- High price target
- $7.00
- Low price target
- $4.20
- Low target gap
- +208.8%
- Target upside
- +306.3%
- High target gap
- +414.7%
- Target range width
- 205.9%
- Consensus rating
- Strong Buy
- Analysts
- 8
- Evidence date
- August 30, 2026
- Valid through
- September 6, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for iBio?
iBio has a verified Strong Buy consensus. The same dataset has an average price target of $5.53.
How far are iBio's low and high targets from the recorded price?
The low target implies +208.8%, while the high target implies +414.7%.
How many analysts are included in iBio's consensus?
The verified consensus includes 8 analysts.
How is iBio's target upside or downside calculated?
The average target of $5.53 is divided by the recorded price of $1.36, then one is subtracted to produce +306.3%. This does not guarantee a future return.
When was iBio's analyst forecast verified?
The data was verified on 2026-08-30. The dataset is valid through 2026-09-06.